Acarbose Reference

Plain English

What it is

Acarbose is a prescription pill approved by the FDA and sold under the brand name Precose. It is approved to help adults with type 2 diabetes, a condition where blood sugar runs too high, get better blood sugar control along with diet and exercise. It works in the gut by slowing how fast the body digests and absorbs sugars from food, which softens the rise in blood sugar after meals.

What people use it for

In the diabetes community it is best known for an older study showing it lowered the chance that people with borderline-high blood sugar went on to develop full type 2 diabetes. In longevity circles people talk about it because it helped male mice live longer in a large aging study, a result that looks similar to the one seen with rapamycin. Using it to slow aging in people is off-label, meaning it is not an approved or proven use for that purpose.

What the science shows

A large human trial found it reduced how often people with pre-diabetes progressed to type 2 diabetes. The longer-life finding came from mice, not people, and mainly affected males. No human trial shows it extends human lifespan or slows aging, and researchers say such studies are still needed.

The catch

Gut side effects like gas, diarrhea, and stomach pain are very common and are the main reason many people pick something else. It can also raise liver enzymes, so the label calls for periodic liver checks, and rare but serious liver problems have been reported. For research and educational purposes only. Not medical advice.

Reference summary

STOP-NIDDM (Chiasson 2002 Lancet, n=1,429 adults with impaired glucose tolerance) demonstrated a 25 percent relative reduction in progression to T2D over a mean 3.3 years on acarbose 100 mg three times daily. The NIA Interventions Testing Program (Strong 2016 Aging Cell) reported lifespan extension in male mice across multiple ITP cohorts when acarbose was started in middle age - a result that parallels rapamycin's ITP signal and is the basis for off-label longevity interest. Human outcome data for longevity-specific endpoints are not available.

Regulatory and posture

Categories

Metabolic, Longevity

Aliases

Precose, Glucobay (international brand), Alpha-glucosidase inhibitor (small molecule, not a peptide)

Evidence posture

human - Off-label longevity use is investigational; the ITP mouse-lifespan signal is the main rationale and is not equivalent to human outcome evidence.

Regulatory status

FDA-approved as Precose (1995) for type 2 diabetes as an adjunct to diet and exercise, alone or with sulfonylureas, metformin, or insulin. Off-label longevity use is investigational; the longevity hypothesis rests primarily on the NIA Interventions Testing Program mouse-lifespan data plus the STOP-NIDDM prevention-of-T2D trial.

Content review status

label verified